Combined Curcumin and EGCG Target Key Markers in Hepatocellular and Colorectal Cancers
Sandhya Varma Suresh, MS
West Texas A&#x0026;M University, 2501 4<sup>th</sup> Avenue, Canyon, TX 79016, USA
Donna M. Byers, PhD
West Texas A&#x0026;M University, 2501 4<sup>th</sup> Avenue, Canyon, TX 79016, USA


Cancer targets
Colorectal cancer
Hepatocellular carcinoma


Objective: Incidence rates of colon and liver cancers differ dramatically between Northern vs. Southern India. It has been suggested that differences in regional diet may play a role, specifically in the disparity in consumption rates of curcumin, an active agent of turmeric, and epigallocatechin gallate (EGCG), a compound in green tea. Curcumin and EGCG have well-known multi-targeted and beneficial effects as chemopreventive agents. However, natural compounds typically require high concentrations to be effective, which can also negatively impact healthy cells. Alternatively, low-dose combination of these compounds, if proven effective, may be one way to avoid this problem. This study proposed to demonstrate the effects of individual and combined treatments of EGCG and curcumin on viability and cancer pathway signaling, in hepatocellular carcinoma (HCC) and colorectal cancer (CCR) cell lines.

Methods: HCC and CCR cell lines (HepG2 and SW1417, respectively) were treated with curcumin and EGCG in a dose- and time-dependent manner. Regorafenib, a chemotherapeutic used to treat colon and liver cancers, was then combined with the effective low-dose EGCG/curcumin. Cell viability, proliferation, and expression of cancer target genes were assessed.

Results: Low-dose combination of curcumin and EGCG influenced the expression of 28 cancer target genes in HepG2 and 14 genes in SW1417. Six of these targets were verified by quantitative polymerase chain reaction. Regorafenib treatment elicited an effect similar to curcumin + EGCG treatment in a number of these targets and enhanced their regulation when used in combination.

Conclusions: Low-dose combinations of curcumin and EGCG have a beneficial effect on regulating important cancer targets in HepG2 and SW1417 cell lines. The data suggest a supportive role for phytochemicals as complementary treatments to chemotherapy.










1. Heron M. Deaths: leading causes for 2017. Natl Vital Stat Rep. 2019;68:1–77.
2. Kumar D, Kumar M, Saravanan C, Singh SK. Curcumin: a potential candidate for matrix metalloproteinase inhibitors. Expert Opin Ther Targets. 2012;16(10):959–72.
3. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007;27(1):55–76.
4. Le Marchand L, Wilkens LR, Hankin JH, et al. A case-control study of diet and colorectal cancer in a multiethnic population in Hawaii (United States): lipids and foods of animal origin. Cancer Causes Control. 1997;8(4):637–48.
5. Lin JK, Chang SC, Yang YC, Li AF. Loss of heterozygosity and DNA aneuploidy in colorectal adenocarcinoma. Ann Surg Oncol. 2003;10(9):1086–94.
6. Takayama T, Miyanishi K, Hayashi T, et al. Colorectal cancer: genetics of development and metastasis. J Gastroenterol. 2006;41(3):185–92.
7. Wang H, Khor TO, Shu L, et al. Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem. 2012;12(10):1281–305.
8. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA. 1995;92(12):5258–65.
9. Quideau S, Deffieux D, Douat-Casassus C, Pouysegu L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew Chem Int Ed Engl. 2011;50(3):586–621.
10. Shimizu M, Adachi S, Masuda M, et al. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol Nutr Food Res. 2011;55(6):832–43.
11. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189–95.
12. Agrawal DK, Mishra PK. Curcumin and its analogues: potential anticancer agents. Med Res Rev. 2010;30(5):818–60.
13. Takeuchi T, Ishidoh T, Iijima H, et al. Structural relationship of curcumin derivatives binding to the BRCT domain of human DNA polymerase lambda. Genes Cells. 2006;11(3):223–35.
14. Shin HJ, Baek KH, Jeon AH, et al. Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell. 2003;4(6):483–97.
15. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725–34.
16. Bhattacharyya S, Mandal D, Saha B, et al. Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem. 2007;282(22):15954–64.
17. Prasad CP, Rath G, Mathur S, et al. Potent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/beta-catenin signaling. Chem Biol Interact. 2009;181(2):263–71.
18. Rinaldi R, Eliasson E, Swedmark S, Morgenstern R. Reactive intermediates and the dynamics of glutathione transferases. Drug Metab Dispos. 2002;30(10):1053–8.
19. Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal. 2008;10(3):511–45.
20. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283–99.
21. Fajardo AM, Piazza GA. Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol. 2015;309(2):G59–70.
22. Sigler K, Ruch RJ. Enhancement of gap junctional intercellular communication in tumor promotertreated cells by components of green tea. Cancer Lett. 1993;69(1):15–9.
23. Gupta S, Hastak K, Afaq F, et al. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene. 2004;23(14):2507–22.
24. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 2001;7(12):4220–9.
25. Kissel M, Berndt S, Fiebig L, et al. Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma. Oncotarget. 2017;8(63):107096–108.
26. Rolfo C, Bronte G, Sortino G, et al. The role of targeted therapy for gastrointestinal tumors. Expert Rev Gastroenterol Hepatol. 2014;8(8):875–85.
27. Aggarwal ML, Chacko KM, Kuruvilla BT. Systematic and comprehensive investigation of the toxicity of curcuminoidessential oil complex: a bioavailable turmeric formulation. Mol Med Rep. 2016;13(1):592–604.
28. Wenger RH, Gassmann M. Oxygen(es) and the hypoxiainducible factor-1. Biol Chem. 1997;378(7):609–16.
29. Chandel NS, Simon MC. Hypoxia-inducible factor: roles in development, physiology, and disease. Cell Death Differ. 2008;15(4):619–20.
30. Liang Y, Li WW, Yang BW, et al. Aryl hydrocarbon receptor nuclear translocator is associated with tumor growth and progression of hepatocellular carcinoma. Int J Cancer. 2012;130(8):1745–54.
31. Kozak KR, Abbott B, Hankinson O. ARNT-deficient mice and placental differentiation. Dev Biol. 1997;191(2):297–305.
32. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2(1):48–58.
33. Huang CR, Lee CT, Chang KY, et al. Down-regulation of ARNT promotes cancer metastasis by activating the fibronectin/integrin beta1/FAK axis. Oncotarget. 2015;6(13):11530–46.
34. Rychli K, Huber K, Wojta J. Pigment epitheliumderived factor (PEDF) as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets. 2009;13(11):1295–302.
35. Hoshina D, Abe R, Yamagishi SI, Shimizu H. The role of PEDF in tumor growth and metastasis. Curr Mol Med. 2010;10(3):292–5.
36. Wietecha MS, Krol MJ, Michalczyk ER, et al. Pigment epithelium-derived factor as a multifunctional regulator of wound healing. Am J Physiol Heart Circ Physiol. 2015;309(5):H812–26.
37. Becerra SP, Notario V. The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nature Rev. 2013;13(4):258–71.
38. Xu B, Li J, Liu X, et al. TXNDC5 is a cervical tumor susceptibility gene that stimulates cell migration, vasculogenic mimicry and angiogenesis by down-regulating SERPINF1 and TRAF1 expression. Oncotarget. 2017;8(53):91009–24.
39. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets. 2009;9(5):639–51.
40. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7(3):165–97.
41. Ahmad A, Sakr WA, Rahman KM. Novel targets for detection of cancer and their modulation by chemopreventive natural compounds. Front Bioscience (Elite Ed). 2012;4:410–25.
42. Tanghetti E, Ria R, Dell’Era P, et al. Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene. 2002;21(24):3889–97.
43. Dell’Era P, Coco L, Ronca R, et al. Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. Oncogene. 2002;21(15):2433–40.
44. Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010;70(6):2213–23.
45. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005;118(Pt 4):771–80.
46. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology. 2003;37(5):1105–13.
47. Zeng H, He X, Tuo QH, et al. LPS causes pericyte loss and microvascular dysfunction via disruption of Sirt3/angiopoietins/Tie-2 and HIF-2alpha/Notch3 pathways. Sci Rep. 2016;6:20931.
48. Evdokimova V, Tognon CE, Benatar T, et al. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal. 2012;5(255):ra92.
49. Pen A, Moreno MJ, Durocher Y, et al. Glioblastomasecreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling. Oncogene. 2008;27(54):6834–44.
50. Akiel M, Guo C, Li X, et al. IGFBP7 deletion promotes hepatocellular carcinoma. Cancer Res. 2017;77(15):4014–25.
51. Rupp C, Scherzer M, Rudisch A, et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. Oncogene. 2015;34(7):815–25.
52. Chen D, Yoo BK, Santhekadur PK, et al. Insulin-like growth factor-binding protein-7 functions as a potential tumor suppressor in hepatocellular carcinoma. Clin Cancer Res. 2011;17(21): 6693–701.
53. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.
54. Basu P, Maier C, Basu A. Effects of curcumin and its different formulations in preclinical and clinical studies of peripheral neuropathic and postoperative pain: a comprehensive review. Int J Mol Sci. 2021;22(9): 4666.
55. Kabir MT, Rahman MH, Akter R, et al. Potential role of curcumin and its nanoformulations to treat various types of cancers. Biomolecules. 2021;11(3):392.
56. Kurita T, Makino Y. Novel curcumin oral delivery systems. Anticancer Res. 2013;33(7):2807–21.
57. Suganuma M, Okabe S, Sueoka N, et al. Green tea and cancer chemoprevention. Mutat Res. 1999;428(1–2):339–44.
58. Chen Y, Jia D, Wang Q, et al. Promotion of the anticancer activity of curcumin based on a metalpolyphenol networks delivery system. Int J Pharm. 2021;602:120650.
59. Moorthy M, Sundralingam U, Palanisamy UD. Polyphenols as prebiotics in the management of high-fat diet-induced obesity: a systematic review of animal studies. Foods. 2021;10(2):299.
60. Pasinetti GM, Singh R, Westfall S, et al. The role of the gut microbiota in the metabolism of polyphenols as characterized by gnotobiotic mice. J Alzheimers Dis. 2018;63(2):409–21.
61. Singh RK, Chang HW, Yan D, et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med. 2017;15(1):73.
62. McFadden RM, Larmonier CB, Shehab KW, et al. The role of curcumin in modulating colonic microbiota during colitis and colon cancer prevention. Inflamm Bowel Dis. 2015;21(11):2483–94.
63. Saydam O, Saydam N. Deficiency of Ku induces host cell exploitation in human cancer cells. Front Cell Dev Biol. 2021;9:651818.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.